MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
7.55
-0.52
-6.44%
After Hours: 7.51 -0.04 -0.57% 18:40 03/27 EDT
OPEN
8.02
PREV CLOSE
8.07
HIGH
8.08
LOW
7.53
VOLUME
2.82M
TURNOVER
--
52 WEEK HIGH
16.44
52 WEEK LOW
5.80
MARKET CAP
1.64B
P/E (TTM)
-5.3158
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Rhythm Pharmaceuticals (RYTM)
TipRanks · 1d ago
Weekly Report: what happened at OCUL last week (0316-0320)?
Weekly Report · 5d ago
EyePoint sues Ocular over claims related to lead asset
Seeking Alpha · 6d ago
EyePoint Files Lawsuit Against Ocular Therapeutix Alleging Defamation And Misleading Claims Over DURAVYU Clinical Results
Benzinga · 03/20 20:39
EyePoint sues Ocular Therapeutix over alleged false statements about DURAVYU clinical results
Reuters · 03/20 20:34
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Seeking Alpha · 03/19 18:37
Weekly Report: what happened at OCUL last week (0309-0313)?
Weekly Report · 03/16 10:26
Ocular Therapeutix grants inducement equity awards covering 60,175 stock options and 19,975 RSUs
Reuters · 03/09 20:01
More
About OCUL
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.